GlassScriptPhysician profile
Julie C Pass
NPI 1003815317
$2,774.27
in general payments reported to CMS, 2019-2025
24 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $235 · 2021: $399 · 2022: $598 · 2023: $406 · 2024: $407 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.38 | 2019-2025 | |
| Exact Sciences Corporation | $234.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Myovant Sciences INC. | $155.45 | 2021-2022 | |
| Biogen, INC. | $152.10 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $146.16 | 2023-2025 | Veozah |
| Axonics, INC. | $141.23 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $135.29 | 2021 | |
| Coopersurgical, INC. | $112.74 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $95.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.83 | 2019-2022 | |
| Hologic Sales and Service, LLC | $90.14 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $89.86 | 2023-2024 | Myfembree |
| Aspira Women'S Health INC | $80.00 | 2023 | Ova1 |
| Kvk-Tech, INC. | $69.60 | 2019 | |
| Organon LLC | $64.67 | 2023-2024 | Nexplanon |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.73 | 2021-2023 | |
| Millicent US INC | $43.69 | 2019-2024 | Intrarosa, Femring |
| Medicem INC. | $31.94 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $22.30 | 2019-2020 | |
| Evofem Biosciences, INC. | $19.43 | 2025 | Solosec, Phexx, Phexxi |
| Medtronic, INC. | $14.89 | 2023 | Venaseal |
| Avion Pharmaceuticals | $14.17 | 2019 | |
| Sage Therapeutics, LLC | $11.08 | 2021 | |
| Lupin INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Pass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.